Granahan Investment Management LLC Has $13.04 Million Stock Holdings in Kiniksa Pharmaceuticals International, plc $KNSA

Granahan Investment Management LLC increased its position in Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) by 11.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 316,213 shares of the company’s stock after buying an additional 32,642 shares during the period. Granahan Investment Management LLC’s holdings in Kiniksa Pharmaceuticals International were worth $13,044,000 at the end of the most recent reporting period.

Several other large investors also recently made changes to their positions in the company. Mark Sheptoff Financial Planning LLC grew its stake in shares of Kiniksa Pharmaceuticals International by 1.6% in the 4th quarter. Mark Sheptoff Financial Planning LLC now owns 16,350 shares of the company’s stock valued at $674,000 after buying an additional 250 shares during the period. Mariner LLC grew its stake in shares of Kiniksa Pharmaceuticals International by 2.0% in the 4th quarter. Mariner LLC now owns 13,519 shares of the company’s stock valued at $558,000 after buying an additional 266 shares during the period. EverSource Wealth Advisors LLC grew its stake in shares of Kiniksa Pharmaceuticals International by 140.4% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 911 shares of the company’s stock valued at $25,000 after buying an additional 532 shares during the period. CWM LLC grew its stake in shares of Kiniksa Pharmaceuticals International by 3.9% in the 4th quarter. CWM LLC now owns 20,605 shares of the company’s stock valued at $850,000 after buying an additional 764 shares during the period. Finally, Wealth Enhancement Advisory Services LLC grew its stake in shares of Kiniksa Pharmaceuticals International by 4.9% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 16,424 shares of the company’s stock valued at $701,000 after buying an additional 771 shares during the period. 53.95% of the stock is currently owned by institutional investors and hedge funds.

Kiniksa Pharmaceuticals International Stock Down 0.1%

Shares of NASDAQ KNSA opened at $52.30 on Wednesday. Kiniksa Pharmaceuticals International, plc has a twelve month low of $26.27 and a twelve month high of $59.87. The stock’s 50 day moving average price is $50.64 and its 200-day moving average price is $46.10. The company has a market capitalization of $4.02 billion, a PE ratio of 58.11 and a beta of 0.12.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last announced its earnings results on Tuesday, April 28th. The company reported $0.27 earnings per share for the quarter, topping analysts’ consensus estimates of $0.18 by $0.09. Kiniksa Pharmaceuticals International had a return on equity of 13.26% and a net margin of 9.69%.The firm had revenue of $214.27 million for the quarter, compared to the consensus estimate of $206.11 million. During the same quarter in the previous year, the business earned $0.11 EPS. The company’s revenue was up 55.5% compared to the same quarter last year. As a group, research analysts expect that Kiniksa Pharmaceuticals International, plc will post 1.24 EPS for the current fiscal year.

Analysts Set New Price Targets

Several analysts have recently commented on KNSA shares. Canaccord Genuity Group raised their target price on Kiniksa Pharmaceuticals International from $62.00 to $64.00 and gave the company a “buy” rating in a research note on Wednesday, April 29th. Wells Fargo & Company raised their price target on shares of Kiniksa Pharmaceuticals International from $53.00 to $57.00 and gave the company an “overweight” rating in a research report on Wednesday, April 29th. Zacks Research raised shares of Kiniksa Pharmaceuticals International from a “strong sell” rating to a “hold” rating in a research report on Monday, May 18th. Wedbush raised their price target on shares of Kiniksa Pharmaceuticals International from $58.00 to $59.00 and gave the company an “outperform” rating in a research report on Wednesday, April 29th. Finally, Jefferies Financial Group raised their price target on shares of Kiniksa Pharmaceuticals International from $58.00 to $71.00 and gave the company a “buy” rating in a research report on Tuesday, April 28th. Eight analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $60.86.

Insider Transactions at Kiniksa Pharmaceuticals International

In other news, CEO Sanj K. Patel sold 483,654 shares of the business’s stock in a transaction that occurred on Tuesday, April 28th. The stock was sold at an average price of $51.86, for a total value of $25,082,296.44. Following the transaction, the chief executive officer owned 431,904 shares in the company, valued at $22,398,541.44. The trade was a 52.83% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Barry D. Quart sold 13,099 shares of the business’s stock in a transaction that occurred on Tuesday, April 28th. The stock was sold at an average price of $50.10, for a total value of $656,259.90. Following the completion of the transaction, the director owned 12,546 shares in the company, valued at $628,554.60. The trade was a 51.08% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 653,301 shares of company stock worth $34,046,073. 51.98% of the stock is owned by insiders.

Kiniksa Pharmaceuticals International Profile

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.